X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs IPCA LABS - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA IPCA LABS ASTRAZENECA PHARMA/
IPCA LABS
 
P/E (TTM) x 103.2 42.1 245.2% View Chart
P/BV x 14.7 3.2 455.4% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   IPCA LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
IPCA LABS
Mar-17
ASTRAZENECA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,285643 199.8%   
Low Rs634503 126.1%   
Sales per share (Unadj.) Rs189.6254.4 74.5%  
Earnings per share (Unadj.) Rs-0.216.1 -1.3%  
Cash flow per share (Unadj.) Rs3.829.8 12.9%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs68.6194.6 35.3%  
Shares outstanding (eoy) m25.00126.20 19.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.3 224.7%   
Avg P/E ratio x-4,712.735.7 -13,219.0%  
P/CF ratio (eoy) x249.619.2 1,297.1%  
Price / Book Value ratio x14.02.9 474.7%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m23,98872,300 33.2%   
No. of employees `0001.613.3 11.7%   
Total wages/salary Rs m1,6056,960 23.1%   
Avg. sales/employee Rs Th3,040.22,413.5 126.0%   
Avg. wages/employee Rs Th1,029.2523.2 196.7%   
Avg. net profit/employee Rs Th-3.3152.4 -2.1%   
INCOME DATA
Net Sales Rs m4,74032,106 14.8%  
Other income Rs m92226 40.8%   
Total revenues Rs m4,83232,332 14.9%   
Gross profit Rs m-1304,448 -2.9%  
Depreciation Rs m1011,730 5.9%   
Interest Rs m0241 0.0%   
Profit before tax Rs m-1392,703 -5.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5675 0.8%   
Profit after tax Rs m-52,028 -0.3%  
Gross profit margin %-2.713.9 -19.8%  
Effective tax rate %-3.725.0 -14.7%   
Net profit margin %-0.16.3 -1.7%  
BALANCE SHEET DATA
Current assets Rs m2,72617,340 15.7%   
Current liabilities Rs m2,4359,559 25.5%   
Net working cap to sales %6.124.2 25.4%  
Current ratio x1.11.8 61.7%  
Inventory Days Days74100 73.5%  
Debtors Days Days4157 71.7%  
Net fixed assets Rs m1,03520,779 5.0%   
Share capital Rs m50252 19.8%   
"Free" reserves Rs m94224,499 3.8%   
Net worth Rs m1,71624,553 7.0%   
Long term debt Rs m03,517 0.0%   
Total assets Rs m4,15639,595 10.5%  
Interest coverage xNM12.2-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.8 140.6%   
Return on assets %-0.15.7 -2.1%  
Return on equity %-0.38.3 -3.6%  
Return on capital %010.5 0.0%  
Exports to sales %5.748.6 11.7%   
Imports to sales %6.514.2 45.4%   
Exports (fob) Rs m27015,617 1.7%   
Imports (cif) Rs m3064,571 6.7%   
Fx inflow Rs m37515,617 2.4%   
Fx outflow Rs m4705,828 8.1%   
Net fx Rs m-969,790 -1.0%   
CASH FLOW
From Operations Rs m-82,764 -0.3%  
From Investments Rs m-146-1,432 10.2%  
From Financial Activity Rs m862-1,591 -54.2%  
Net Cashflow Rs m709-259 -273.8%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.4 2.6%  
FIIs % 15.7 25.3 62.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.4 52.3%  
Shareholders   12,856 36,892 34.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Losses; Capital Goods Sector Down 1.7%(11:30 am)

Indian share markets are presently trading on a negative note. Sectoral indices are trading in the red with stocks in the capital goods sector and metal sector witnessing maximum selling pressure.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 19, 2018 12:27 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS